PD-BT2278

PD-BT2278 is a preclinical-stage therapeutic candidate being developed by BioArctic for the treatment of Parkinson's disease. The drug utilizes BioArctic's proprietary BrainTransporter (BT) technology, a blood-brain barrier (BBB) delivery platform designed to facilitate the active transport of biologics into the central nervous system. PD-BT2278 consists of a therapeutic antibody—likely targeting alpha-synuclein—linked to a monovalent binder that targets the transferrin receptor (TfR). By leveraging TfR-mediated transcytosis, the BT technology aims to increase brain exposure of the antibody by several-fold compared to standard antibodies, potentially improving the clearance of pathological protein aggregates and enhancing clinical efficacy in neurodegenerative disorders.